Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The impact of COVID-19 on inflammatory bowel disease (IBD) patients under pharmacological immunosuppression is still not clearly understood. We investigated the incidence of COVID-19 and the impact of immunosuppression and containment measures on the risk of SARS-CoV-2 infection in a large IBD cohort, from a multicenter cohort from 21st of February to 30th of June, 2020. Ninety-seven patients with IBD (43 UC, 53 CD, one unclassified IBD) and concomitant COVID-19 over a total of 23,879 patients with IBD were enrolled in the study. The cumulative incidence of SARS-CoV-2 infection in patients with IBD vs. the general population was 0.406% and 0.402% cases, respectively. Twenty-three patients (24%) were hospitalized, 21 (22%) had pneumonia, four (4%) were admitted to the Intensive Care Unit, and one patient died. Lethality in our cohort was 1% compared to 9% in the general population. At multivariable analysis, age > 65 years was associated with increased risk of pneumonia and hospitalization (OR 11.6, 95% CI 2.18-62.60; OR 5.1, 95% CI 1.10-23.86, respectively), treatment with corticosteroids increased the risk of hospitalization (OR 7.6, 95% CI 1.48-40.05), whereas monoclonal antibodies were associated with reduced risk of pneumonia and hospitalization (OR 0.1, 95% CI 0.04-0.52; OR 0.3, 95% CI 0.10-0.90, respectively). The risk of COVID-19 in patients with IBD is similar to the general population. National lockdown was effective in preventing infection in our cohort. Advanced age and treatment with corticosteroids impacted negatively on the outcome of COVID-19, whereas monoclonal antibodies did not seem to have a detrimental effect.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693947 | PMC |
| http://dx.doi.org/10.3390/jcm9113533 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sarcopenia-A Valuable Imaging Biomarker for Disease Progression in Patients With Primary Sclerosing Cholangitis (PSC)?
Liver Int
October 2025
Hannover Medical School, Department of Diagnostic and Interventional Radiology, Hannover, Germany.
Background And Aims: We aimed to ascertain the prevalence of sarcopenia in patients with primary sclerosing cholangitis (PSC) and to assess the prognostic value as a biomarker for disease outcome.
Methods: We collected data from 224 patients (148 male, 76 female; mean age 41 years) from January 2002 to December 2021, with a confirmed diagnosis of PSC who underwent magnetic resonance imaging (MRI). Muscle mass was quantified at the level of the third lumbar vertebra by measurement of psoas muscle thickness (PMT) and total psoas muscle area (PMA).
The Role of Endometriosis in Intestinal Inflammation: A Combined Mendelian Randomization and Cellular Study.
J Cell Mol Med
September 2025
Department of Obstetrics and Gynecology, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
This study aims to assess whether endometriosis causally increases the risk of IBD through Mendelian randomisation (MR) analysis and to elucidate potential mechanisms using in vitro experiments. A two-sample Mendelian randomisation (MR) analysis was conducted using genome-wide association study datasets for endometriosis and IBD, including ulcerative colitis and Crohn's disease. Causal inference was assessed using inverse variance weighting, MR-Egger, and weighted median methods, with MR-PRESSO used to detect horizontal pleiotropy.
View Article and Find Full Text PDFRole of ETS2 gene in inflammatory bowel disease: A narrative review.
Medicine (Baltimore)
September 2025
Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan.
The ETS2 gene, a member of the ETS (E26 transformation-specific) family of transcription factors, plays a critical role in the regulation of immune responses, epithelial barrier integrity, and fibrosis, all of which are central to the pathogenesis of inflammatory bowel disease (IBD). This review explores the molecular characteristics of ETS2, its involvement in immune dysregulation, and its contribution to IBD-associated complications, including fibrosis and colorectal cancer. ETS2 regulates key inflammatory pathways such as NF-κB and JAK-STAT, influencing cytokine production and immune cell polarization.
View Article and Find Full Text PDFAssociation of Autoimmune Disease with Melanoma and Non-Melanoma Skin Cancers.
Clin Exp Dermatol
September 2025
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
This study examines the association between autoimmune diseases and melanoma and non-melanoma skin cancer using data from the All of Us Research Program. We conducted a cross-sectional analysis including 419,789 participants using multivariable logistic regression models adjusting for sociodemographic variables, comorbidities, and immunosuppressant use. We found significant associations between melanoma and Sjögren's syndrome, inflammatory bowel disease (IBD), vitiligo, and autoimmune thyroiditis.
View Article and Find Full Text PDFLong-Term Risk of Inflammatory Bowel Disease in Autoimmune Hepatitis: over a 20-Year Population-Based Study.
Clin Res Hepatol Gastroenterol
September 2025
Clalit Health Services, Northern Region, Israel; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Background: Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease with a recognized, but incompletely defined, association with inflammatory bowel disease (IBD). The long-term risk of developing IBD in AIH patients and its influence on hepatic outcomes remain unclear.
Aim: To determine the incidence and risk factors for IBD in a large AIH cohort over a 20-year follow-up and to assess its impact on liver-related complications.